Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABSIOTCMKTS:CBWTFNASDAQ:MXCTNASDAQ:NRC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABSIAbsci$2.66$2.83$2.01▼$6.33$339.31M2.192.74 million shs2.03 million shsCBWTFAuxly Cannabis Group$0.06-4.2%$0.06$0.02▼$0.07$81.41M11.14 million shs162,120 shsMXCTMaxCyte$2.19-2.7%$2.61$2.10▼$5.26$232.84M1.38587,167 shs1.54 million shsNRCNational Research$13.59-1.5%$12.54$9.76▼$30.79$309.65M0.3496,258 shs82,135 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABSIAbsci-1.48%-10.14%-17.13%-46.32%-42.30%CBWTFAuxly Cannabis Group+1.09%-5.27%+11.17%+40.65%+77.75%MXCTMaxCyte+2.27%+0.90%-17.58%-41.62%-51.09%NRCNational Research+2.99%-1.36%+29.00%-11.66%-55.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABSIAbsci2.5015 of 5 stars3.53.00.00.03.30.80.6CBWTFAuxly Cannabis Group0.0737 of 5 stars0.03.00.00.00.60.00.0MXCTMaxCyte2.838 of 5 stars3.52.00.00.02.72.51.3NRCNational Research1.2139 of 5 stars0.02.01.70.01.12.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABSIAbsci 3.00Buy$8.40215.79% UpsideCBWTFAuxly Cannabis Group 0.00N/AN/AN/AMXCTMaxCyte 3.00Buy$7.50242.47% UpsideNRCNational Research 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CBWTF, ABSI, NRC, and MXCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ABSIAbsciNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/16/2025ABSIAbsciKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $9.004/9/2025ABSIAbsciNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/20/2025ABSIAbsciGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/19/2025ABSIAbsciHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/19/2025ABSIAbsciNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/12/2025MXCTMaxCyteBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$6.003/12/2025MXCTMaxCyteStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $9.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABSIAbsci$4.82M70.47N/AN/A$1.90 per share1.40CBWTFAuxly Cannabis Group$74.87M1.09N/AN/A$0.04 per share1.55MXCTMaxCyte$37.68M6.18N/AN/A$2.23 per share0.98NRCNational Research$141.30M2.19$1.26 per share10.81$2.02 per share6.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABSIAbsci-$110.57M-$0.92N/AN/AN/A-2,321.56%-46.56%-39.74%N/ACBWTFAuxly Cannabis Group-$32.97M$0.01N/A∞N/A-65.48%-80.40%-28.61%N/AMXCTMaxCyte-$37.92M-$0.40N/AN/AN/A-78.36%-16.00%-13.93%8/5/2025 (Estimated)NRCNational Research$24.78M$1.0312.94∞N/A17.32%66.52%20.00%8/11/2025 (Estimated)Latest CBWTF, ABSI, NRC, and MXCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CBWTFAuxly Cannabis GroupN/A$0.01N/A$0.01N/AN/A5/13/2025Q1 2025ABSIAbsci-$0.23-$0.21+$0.02-$0.21$1.07 million$1.18 million5/7/2025Q1 2025MXCTMaxCyte-$0.10-$0.10N/A-$0.10$9.05 million$10.39 million4/28/2025Q1 2025NRCNational ResearchN/A$0.25N/A$0.25N/A$33.55 million3/18/2025Q4 2024ABSIAbsci-$0.22-$0.25-$0.03-$0.25$1.77 million$0.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABSIAbsciN/AN/AN/AN/AN/ACBWTFAuxly Cannabis GroupN/AN/AN/AN/AN/AMXCTMaxCyteN/AN/AN/AN/AN/ANRCNational Research$0.483.53%N/A46.60%N/ALatest CBWTF, ABSI, NRC, and MXCT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025NRCNational Researchquarterly$0.124.1%6/27/20256/27/20257/11/20253/24/2025NRCNational Researchquarterly$0.123.27%3/28/20253/28/20254/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABSIAbsci0.015.635.63CBWTFAuxly Cannabis Group0.370.850.48MXCTMaxCyteN/A9.819.22NRCNational Research1.300.470.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABSIAbsci52.05%CBWTFAuxly Cannabis GroupN/AMXCTMaxCyte68.81%NRCNational Research47.26%Insider OwnershipCompanyInsider OwnershipABSIAbsci9.81%CBWTFAuxly Cannabis Group4.60%MXCTMaxCyte3.00%NRCNational Research8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABSIAbsci210127.56 million103.59 millionOptionableCBWTFAuxly Cannabis Group3691.31 billion1.25 billionNot OptionableMXCTMaxCyte80106.32 million102.67 millionOptionableNRCNational Research49022.79 million23.01 millionOptionableCBWTF, ABSI, NRC, and MXCT HeadlinesRecent News About These CompaniesMedirex receives funding to modernise patient authenticationMay 22 at 7:38 AM | finance.yahoo.comME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory DiseaseMay 21 at 6:37 AM | finance.yahoo.comNRC Withdraws Environmental Justice Policy StatementMay 21 at 1:36 AM | jdsupra.comSeabrook nuclear plant: NRC faces questions on Trump cuts, concrete degradationMay 16, 2025 | seacoastonline.comWhite House Reportedly Weighs Major Nuclear Regulatory ShiftMay 14, 2025 | ijr.comTuesday’s Top Insider Moves: Strategic Buys and Significant SellsMay 14, 2025 | investing.comWhite House weighs NRC overhaulMay 14, 2025 | eenews.netLiving Creatures Cast a Faint Aura That Stops at Death, Study SuggestsMay 14, 2025 | gizmodo.comA Look At The Intrinsic Value Of National Research Corporation (NASDAQ:NRC)May 14, 2025 | finance.yahoo.comNational Research Co. (NASDAQ:NRC) Major Shareholder Purchases $33,975.00 in StockMay 14, 2025 | insidertrades.comNational Research Shareholders Approve 2025 Incentive PlanMay 12, 2025 | tipranks.comUAE's National Rehabilitation Center earns three-year CARF AccreditationMay 11, 2025 | zawya.comNational Rehabilitation Centre earns Three-Year CARF AccreditationMay 11, 2025 | msn.comWhy National Research Corporation’s (NRC) Stock Is Up 5.24%May 2, 2025 | aaii.comNRC Q1 Earnings Dip Y/Y Amid Rising Interest Costs, Shares Up 13%May 2, 2025 | zacks.comINL issues second report recommending improvements to nuclear licensingMay 1, 2025 | jdsupra.comNational Research Co. (NASDAQ:NRC) to Issue $0.12 Quarterly DividendMay 1, 2025 | marketbeat.comNational Research (NASDAQ:NRC) Announces Earnings ResultsApril 30, 2025 | marketbeat.comJPMorgan Chase & Co. Grows Stock Holdings in National Research Co. (NASDAQ:NRC)April 30, 2025 | marketbeat.comNRC Health Announces First Quarter ResultsApril 28, 2025 | businesswire.comWells Fargo & Company MN Has $2.53 Million Stock Holdings in National Research Co. (NASDAQ:NRC)April 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBWTF, ABSI, NRC, and MXCT Company DescriptionsAbsci NASDAQ:ABSI$2.66 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.64 -0.02 (-0.56%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Auxly Cannabis Group OTCMKTS:CBWTF$0.06 0.00 (-4.17%) As of 03:49 PM EasternAuxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. The company was incorporated in 1987 and is headquartered in Toronto, Canada.MaxCyte NASDAQ:MXCT$2.19 -0.06 (-2.67%) Closing price 04:00 PM EasternExtended Trading$2.19 +0.00 (+0.23%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.National Research NASDAQ:NRC$13.59 -0.20 (-1.45%) Closing price 04:00 PM EasternExtended Trading$13.59 0.00 (0.00%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
